Canadian Rx Imports Would Supply 10% Of U.S. Market, Caremark Exec Says
This article was originally published in The Pink Sheet Daily
The limited supply of drugs coming from Canada under a legalized importation system would have little impact on U.S. prices, Caremark CEO Crawford says at PCMA annual meeting. Importation would require PBMs to decide how to distribute lower-priced Canadian products among their clients, he says.
You may also be interested in...
Rx importation will "come to pass one way or another," Healthcare Distribution Management Association CEO John Gray says. An association-commissioned report is designed to demonstrate the value of distributors in the pharmaceutical supply chain.
Caremark sees the potential for legalized wholesale imports from Canada to offer an opportunity analogous to the current profit and savings impact of generic drugs
A bulk importation scheme through certified foreign exporters would require adding safeguards to the existing U.S. distribution system, CVS CEO Ryan tells the HHS importation task force. Primary importation challenge would be ensuring adequate supply